switching from semaglutide to tirzepatide dose dosage guide Tirzepatide vs. Semaglutide for Weight

Mojsov, S

Wegovy : una inyeccin semanal de semaglutida aprobada para el control crnico del peso en personas con obesidad o sobrepeso, especialmente aquellas con complicaciones relacionadas con el peso

Study Design Type: Phase 2, double-blind, randomized, placebo-controlled study Participants: 338 adults (BMI 30 or BMI 27 with a coexisting condition) Groups: Retatrutide 1 mg, 4 mg, 8 mg, 12 mg (different initial doses 2 or 4 mg) and placebo Duration: 48 weeks (plus 4 weeks follow-up) Administration: subcutaneous, 1x weekly Primary endpoint: percentage change in body weight at week 24 Secondary endpoints: change in weight at week 48, 5%, 10%, 15% weight reduction

You may be eating less, which makes you feel hungry again after meals

They monitor how their body reacts to different foods, adjust their protein intake based on how full they feel, and identify which side effects indicate they need to adjust their approach